$HUM

Raymond James Upgrades Humana to Outperform From Market Perform, Price Target is $520

Raymond James upgraded Humana to Outperform from Market Perform, setting a price target of $520. The stock has risen 11.56% in 5 days and 68.61% year-to-date, according to the article.

Original reporting
Published Oct 12, 2026, 11:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 12, 2026, 11:57 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$HUM
Bullish
high confidence
Mentioned
$HUM
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$HUMBullishMed
01

Why it matters

The upgrade is the primary new information; no earnings or other corporate events are disclosed.

02

Market read

A fresh analyst upgrade with a concrete price target can prompt short‑term buying pressure.

03

What to watch

No disclosed earnings or guidance change accompanies the upgrade.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

The article repeats the analyst's rating methodology without new company data.

Company-level read

Ticker impact

$HUMBullishHigh confidence
Context

Raymond James upgraded Humana to Outperform and set a new price target of $520.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Analyst upgrades are a common catalyst for short‑term price gains, especially with a specific target.

Market effects

May lift sentiment in the health‑care services sector.

U.S. market focus, limited regional effect.

Low global impact beyond U.S. health‑care investors.

Counterpoint

The upgrade could be premature if underlying earnings guidance remains weak.

Key entities

  • Humana Inc.

    U.S. health insurance provider receiving an upgrade.

  • Raymond James

    Equity research firm issuing the upgrade.

Related articles

$HUMMed

Humana (HUM) Gets a Major Ratings Boost. Can Earnings Justify the Valuation?

Humana (HUM) shares rose 11% after analysts highlighted its potential benefits from improved Medicare Advantage star ratings for 2027. The company expects 95% of its members to be in highly-rated plans, up from 20% in 2026, exceeding J.P. Morgan's estimates. Higher ratings could boost future revenue and profitability, with Evercore ISI estimating $4.8B in bonus payments for 2028. However, risks include rising healthcare costs and the need to reinvest in benefits and provider arrangements.

$HUMMedAI 8/10

Humana Rebounds in Medicare Advantage Star Ratings for 2027

Humana's Medicare Advantage star ratings improved significantly for 2027, with 93% of members in plans rated 4 stars or higher, up from 41% in 2026. This could generate $3B+ in additional revenue in 2028, according to TD Cowen. Alignment Healthcare saw a major decline, potentially losing $170M in revenue. CMS changed its star ratings methodology for 2027.